Sheila Gujrathi, a director at Ventyx Biosciences, Inc. (NASDAQ:VTYX), recently purchased 130,000 shares of the company’s common stock. The transaction, which took place on December 23, 2024, involved a total expenditure of approximately $300,573, with shares acquired at an average price of $2.3121. The purchase comes as the stock trades near $2.33, significantly below its 52-week high of $11.48. According to InvestingPro analysis, the company currently appears undervalued based on its Fair Value metrics. According to the filing, these shares are held by the Jordan Yechiel Cohen and Sheila Kumari Gujrathi AB Living Trust, where Gujrathi serves as a co-trustee. This acquisition reflects Gujrathi’s continued investment in Ventyx Biosciences, which maintains a strong liquidity position with a current ratio of 23.52 and more cash than debt on its balance sheet. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report for deeper analysis of VTYX’s financial health and growth prospects.
In other recent news, Ventyx Biosciences reported long-term efficacy data from its Phase 2 study of tamuzimod, a treatment for ulcerative colitis, which achieved its primary endpoint of clinical remission. The company also disclosed a significant $27 million investment from pharmaceutical giant Sanofi (NASDAQ:SNY), tied to Ventyx’s drug candidate for Parkinson’s disease and obesity, VTX3232. Changes in leadership were announced with CFO Martin Auster stepping down and Roy Gonzales stepping in as interim Principal Financial (NASDAQ:PFG) Officer and Principal Accounting Officer.
Ventyx Biosciences reported a net quarterly loss of $38.6 million, with cash, cash equivalents, and marketable securities totaling $279.7 million. Analyst notes reveal that Piper Sandler maintained its Overweight rating for the company, while Oppenheimer retained an Outperform rating despite reducing its price target. H.C. Wainwright continues to hold a Neutral stance on Ventyx Biosciences.
Despite the Phase 2 trial of Ventyx’s drug, VTX958, not meeting its primary goal in treating Crohn’s disease, it did show a positive impact on a key secondary endpoint. However, the company indicated it will not conduct further trials of VTX958 with its internal resources. These are among the recent developments at the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.